Related references
Note: Only part of the references are listed.Compound cellular stress maximizes apoptosis independently of p53 in glioblastoma
Cheng-Jung Ho et al.
CELL CYCLE (2022)
Separase-triggered apoptosis enforces minimal length of mitosis
Susanne Hellmuth et al.
NATURE (2020)
Transcription-independent and -dependent p53-mediated apoptosis in response to genotoxic and non-genotoxic stress
Cheng-Jung Ho et al.
CELL DEATH DISCOVERY (2019)
Deciphering p53 signaling in tumor suppression
Stephano S. Mello et al.
CURRENT OPINION IN CELL BIOLOGY (2018)
P53 enhances apoptosis induced by doxorubicin only under conditions of severe DNA damage
Ru-Wei Lin et al.
CELL CYCLE (2018)
BCL-2 family proteins: changing partners in the dance towards death
Justin Kale et al.
CELL DEATH AND DIFFERENTIATION (2018)
Serine 392 phosphorylation modulates p53 mitochondrial translocation and transcription-independent apoptosis
Cedric Castrogiovanni et al.
CELL DEATH AND DIFFERENTIATION (2018)
How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?
Brandon J. Aubrey et al.
CELL DEATH AND DIFFERENTIATION (2018)
The role of p53 in cancer drug resistance and targeted chemotherapy
Karin Hientz et al.
ONCOTARGET (2017)
ABT-737 potentiates cisplatin- induced apoptosis in human osteosarcoma cells via the mitochondrial apoptotic pathway
Fengtian Zhang et al.
ONCOLOGY REPORTS (2017)
Proteasome inhibitors: structure and function
Ana T. Nunes et al.
SEMINARS IN ONCOLOGY (2017)
Pediatric osteosarcoma: An updated review
Shachi Jain Taran et al.
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY (2017)
Treatment Pathway of Bone Sarcoma in Children, Adolescents, and Young Adults
Damon R. Reed et al.
CANCER (2017)
Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease
Douglas J. Harrison et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53
Min-Chi Yang et al.
CELL CYCLE (2016)
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial
Sophie Piperno-Neumann et al.
LANCET ONCOLOGY (2016)
Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients
Claudia M. Hattinger et al.
PHARMACOGENOMICS (2016)
The BCL-2 protein family, BH3-mimetics and cancer therapy
A. R. D. Delbridge et al.
CELL DEATH AND DIFFERENTIATION (2015)
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Stefan S. Bielack et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Michael S. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Xiang Chen et al.
CELL REPORTS (2014)
A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis
M. Kracikova et al.
CELL DEATH AND DIFFERENTIATION (2013)
Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients
Xing Wu et al.
CANCER EPIDEMIOLOGY (2012)
Distinct Regulatory Mechanisms and Functions for p53-Activated and p53-Repressed DNA Damage Response Genes in Embryonic Stem Cells
Mangmang Li et al.
MOLECULAR CELL (2012)
Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma
Yuriy Shapovalov et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Transcription-independent p53 apoptosis: an alternative route to death
Daniel Speidel
TRENDS IN CELL BIOLOGY (2010)
Microtubule dynamics as a target in oncology
April L. Risinger et al.
CANCER TREATMENT REVIEWS (2009)
Bortezomib A Review of its Use in Patients with Multiple Myeloma
Monique P. Curran et al.
DRUGS (2009)
Sanguinarine causes DNA damage and p53-independent cell death in human colon cancer cell lines
Smita S. Matkar et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2008)
The genetics of the p53 pathway, apoptosis and cancer therapy
Alexei Vazquez et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
BCL-2 family antagonists for cancer therapy
Guillaume Lessene et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage
Seth D. Berman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
M Groll et al.
STRUCTURE (2006)
The Rb/E2F pathway: expanding roles and emerging paradigms
JW Harbour et al.
GENES & DEVELOPMENT (2000)
Nora, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis
E Oda et al.
SCIENCE (2000)
Share Paper
